How the FDA Is Using AI in Regulatory Review

Ariana Wilson and Mark Drlik seated against a white background, wearing lavalier microphones. The woman on the left has long brown curly hair and is wearing a beige cardigan over a taupe top. The man on the right is wearing glasses and a blue button-up shirt. They appear to be engaged in conversation or a video interview.
Resources

How the FDA Uses AI in Device Review

The FDA AI in device review process is evolving fast—and it may transform how regulatory teams navigate medical device submissions. In this episode of MedDevice by Design, we explore how the FDA is using artificial intelligence internally to accelerate 510(k) reviews, improve predicate searches, and streamline labeling and documentation checks.

FDA’s Internal AI Tools Are Expanding

The FDA has already appointed a Chief AI Officer and is developing internal tools, including a large language model rumored to be in collaboration with OpenAI. Starting in June 2025, these tools are expected to be rolled out across departments. These technologies are designed to support internal staff—not replace them.

Faster Reviews for Common Device Submissions

Class II devices such as blood pressure monitors and surgical gloves may benefit the most from FDA AI in device review workflows. By using trained AI models, reviewers can automate routine predicate searches, validate labeling against regulatory standards, and identify missing traceability in submission documents.

Why This Matters for Regulatory Professionals

While novel and high-risk devices will still require close human evaluation, AI promises to reduce the review burden for standard submissions. This allows regulatory and engineering teams to focus more on innovative product development. Instead of spending weeks preparing repetitive documentation, they can rely on automated feedback to guide improvements faster.

What Comes Next?

There’s still a lot we don’t know, but the FDA is clearly signaling that AI will be part of the future of regulatory review. The ability to streamline standard 510(k) submissions could help improve speed, consistency, and predictability in approvals—benefiting both regulators and medtech innovators.

Split image showing two close-up views of a human eye. On the left, the eye is seen through thick black-framed glasses, indicating impaired vision. On the right, the same eye is enhanced with a futuristic digital overlay of concentric circles and interface elements, suggesting advanced vision restoration technology. A red curved arrow points from left to right, implying improvement. Bold text at the top reads "Restoring Vision?"

Ariana and Mark explore how accommodative intraocular lens technology may one day restore natural vision for people who require cataract surgery or suffer from presbyopia. As Mark shares, traditional bifocals are not ideal, and new lens solutions may offer better outcomes.

Brain-computer interface - A man wearing a brain-computer interface (BCI) headset sits in a clinical setting, concentrating as he appears to control a robotic arm with his mind. His head is overlaid with digital graphics representing brain activity. A doctor in a white lab coat stands nearby, monitoring the interaction. Onscreen data displays in the background suggest medical or neurological analysis. Bold text on the image reads "Brain-Controlled Tech?"

We explore the world of brain-computer interfaces (BCIs) and the challenges of capturing thought into action. Mark Drlik and Ariana Wilson walk through how these systems translate brain activity into control signals for devices—without needing surgical implants.

X-ray image of a human chest showing bones in high contrast. A visible electronic device, likely a pacemaker or implant, is located in the upper left chest area. A bold red arrow points to the device with a label in black and white text reading “definitely not bone.”

Mark and Ariana explore the surprising versatility of barium sulfate—a material used widely in both diagnostic procedures and medical device manufacturing. While many recognize it as the contrast agent you drink before an X-ray, it’s also a key additive that enhances plastic components across the healthcare industry.

Gloved hand holding a test tube filled with red liquid, with a large red arrow pointing at the tube on a blue gradient background.

We explore a groundbreaking shift in how Alzheimer’s disease may soon be diagnosed. Instead of relying on invasive spinal taps or costly PET scans, researchers have developed a blood test that detects key proteins associated with the disease—offering a more accessible and patient-friendly screening method.